Influence of translation efficiency of homologous viral proteins on the endogenous presentation of CD8+ T cell epitopes

Journal of Experimental Medicine

Volumn 204, Issue 3, 2007, Pages 525-532

  Tellam, Judy ^a   Fogg, Mark H ^b   Rist, Michael ^a   Connolly, Geoff ^a   Tscharke, David ^a   Webb, Natasha ^a   Heslop, Lea ^a   Wang, Fred ^b   Khanna, Rajiv ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; EPITOPE; EPSTEIN BARR VIRUS ENCODED NUCLEAR ANTIGEN 1; GAMMA INTERFERON; GLYCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN; POLYPEPTIDE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIGEN DETECTION; ARTICLE; CD8+ T LYMPHOCYTE; CELL STRAIN HEK293; CORRELATION ANALYSIS; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN SYNTHESIS; PROTEIN TRANSPORT;

ANTIGEN PRESENTATION; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CELL LINE, TRANSFORMED; DIPEPTIDES; EPITOPES, T-LYMPHOCYTE; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HUMANS; REPETITIVE SEQUENCES, AMINO ACID; SEQUENCE DELETION; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 33947411798     PISSN: 00221007     EISSN: 00221007     Source Type: Journal    
DOI: 10.1084/jem.20062508     Document Type: Article

References (39)

1. Yewdell, J.W., and S.M. Haeryfar. 2005. Understanding presentation of viral antigens to CD8+ T cells in vivo: the key to rational vaccine design. Annu. Rev. Immunol. 23:651-682.
2. Yewdell, J.W., E. Reits, and J. Neefjes. 2003. Making sense of mass destruction: quantitating MHC class I antigen presentation. Nat. Rev. Immunol. 3:952-961.
3. Yewdell, J.W., U. Schubert, and J.R. Bennink. 2001. At the crossroads of cell biology and immunology: DRiPs and other sources of peptide ligands for MHC class I molecules. J. Cell Sci. 114:845-851.
4. Goldberg, A.L., P. Cascio, T. Saric, and K.L. Rock. 2002. The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Mol. Immunol. 39:147-164.
5. Goldberg, A.L., and K.L. Rock. 1992. Proteolysis, proteasomes and antigen presentation. Nature. 357:375-379.
6. Shastri, N., S. Schwab, and T. Serwold. 2002. Producing nature's genechips: the generation of peptides for display by MHC class I molecules. Annu. Rev. Immunol. 20:463-493.
7. Lehner, P.J. 2003. The calculus of immunity: quantitating antigen processing. Immunity. 18:315-317.
8. Rock, E.P., P.R. Sibbald, M.M. Davis, and Y.H. Chien. 1994. CDR3 length in antigen-specific immune receptors. J. Exp. Med. 179:323-328.
9. Cerundolo, V., A. Benham, V. Braud, S. Mukherjee, K. Gould, B. Macino, J. Neefjes, and A. Townsend. 1997. The proteasome-specific inhibitor lactacystin blocks presentation of cytotoxic T lymphocyte epitopes in human and murine cells. Eur. J. Immunol. 27:336-341.
10. Princiotta, M.F., D. Finzi, S.B. Qian, J. Gibbs, S. Schuchmann, F. Buttgereit, J.R. Bennink, and J.W. Yewdell. 2003. Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity. 18:343-354.
11. Yin, Y., B. Manoury, and R. Fahraeus. 2003. Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. Science. 301:1371-1374.
12. Levitskaya, J., A. Sharipo, A. Leonchiks, A. Ciechanover, and M.G. Masucci. 1997. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc. Natl. Acad. Sci. USA. 94:12616-12621.
13. + T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1. J. Exp. Med. 199:1421-1431.
14. + T lymphocytes. J. Exp. Med. 199:459-470.
15. Lee, S.P., J.M. Brooks, H. Al-Jarrah, W.A. Thomas, T.A. Haigh, G.S. Taylor, S. Humme, A. Schepers, W. Hammerschmidt, J.L. Yates, et al. 2004. CD8 T cell recognition of endogenously expressed Epstein-Barr virus nuclear antigen 1. J. Exp. Med. 199:1409-1420.
16. Yewdell, J.W., L.C. Anton, and J.R. Bennink. 1996. Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? J. Immunol. 157:1823-1826.
17. Yewdell, J.W. 2005. Serendipity strikes twice: the discovery and rediscovery of defective ribosomal products (DRiPS). Cell. Mol. Biol. 51:635-641.
18. Schubert, U., L.C. Anton, J. Gibbs, C.C. Norbury, J.W. Yewdell, and J.R. Bennink. 2000. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature. 404:770-774.
19. Blake, N.W., A. Moghaddam, P. Rao, A. Kaur, R. Glickman, Y.G. Cho, A. Marchini, T. Haigh, R.P. Johnson, A.B. Rickinson, and F. Wang. 1999. Inhibition of antigen presentation by the glycine/alanine repeat domain is not conserved in simian homologues of Epstein-Barr virus nuclear antigen 1. J. Virol. 73:7381-7389.
20. Gonzalez-Garay, M.L., and F. Cabral. 1995. Overexpression of an epitope-tagged beta-tubulin in Chinese hamster ovary cells causes an increase in endogenous alpha-tubulin synthesis. Cell Motil. Cytoskeleton. 31:259-272.
21. Porgador, A., J.W. Yewdell, Y. Deng, J.R. Bennink, and R.N. Germain. 1997. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity. 6:715-726.
22. Burrows, S.R., S.J. Rodda, A. Suhrbier, H.M. Geysen, and D.J. Moss. 1992. The specificity of recognition of a cytotoxic T lymphocyte epitope. Eur. J. Immunol. 22:191-195.
23. Chen, A., M. Divisconte, X. Jiang, C. Quink, and F. Wang. 2005. Epstein-Barr virus with the latent infection nuclear antigen 3B completely deleted is still competent for B-cell growth transformation in vitro. J. Virol. 79:4506-4509.
24. Gandhi, M.K., and R. Khanna. 2004. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect. Dis. 4:725-738.
25. Hilleman, M.R. 2004. Strategies and mechanisms for host and pathogen survival in acute and persistent viral infections. Proc. Natl. Acad. Sci. USA. 101(Suppl 2):14560-14566.
26. Khanna, R., D.J. Moss, and M. Gandhi. 2005. Applications of emerging immunotherapeutic strategies for Epstein-Barr virus-associated malignancies. Nature Clinical Practice. Oncolcogy. 2:138-149.
27. Khanna, R., and S.R. Burrows. 2000. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Annu. Rev. Microbiol. 54:19-48.
28. Apcher, S., R. Fahraeus, and B. Manoury. 2004. Epstein-Barr virus: exploiting the immune system by interfering with defective ribosomal products. Microbes Infect. 6:1212-1218.
29. Yewdell, J.W., and C.V. Nicchitta. 2006. The DRiP hypothesis decennial: support, controversy, refinement and extension. Trends Immunol. 27:368-373.
30. Khan, S., R. de Giuli, G. Schmidtke, M. Bruns, M. Buchmeier, M. van den Broek, and M. Groettrup. 2001. Cutting edge: neosynthesis is required for the presentation of a T cell epitope from a long-lived viral protein. J. Immunol. 167:4801-4804.
31. Probst, H.C., K. Tschannen, A. Gallimore, M. Martinic, M. Basler, T. Dumrese, E. Jones, and M.F. van den Broek. 2003. Immunodominance of an antiviral cytotoxic T cell response is shaped by the kinetics of viral protein expression. J. Immunol. 171:5415-5422.
32. Ostankovitch, M., V. Robila, and V.H. Engelhard. 2005. Regulated folding of tyrosinase in the endoplasmic reticulum demonstrates that misfolded full-length proteins are efficient substrates for class I processing and presentation. J. Immunol. 174:2544-2551.
33. Liu, W.J., F. Gao, K.N. Zhao, W. Zhao, G.J. Fernando, R. Thomas, and I.H. Frazer. 2002. Codon modified human papillomavirus type 16 E7 DNA vaccine enhances cytotoxic T-lymphocyte induction and anti-tumour activity. Virology. 301:43-52.
34. Tellam, J., M. Sherritt, S. Thomson, R. Tellam, D.J. Moss, S.R. Burrows, E. Wiertz, and R. Khanna. 2001. Targeting of EBNA1 for rapid intracellular degradation overrides the inhibitory effects of the Gly-Ala repeat domain and restores CD8+ T cell recognition. J. Biol. Chem. 276:33353-33360.
35. Boukamp, P., R.T. Petrussevska, D. Breitkreutz, J. Hornung, A. Markham, and N.E. Fusenig. 1988. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J. Cell Biol. 106:761-771.
36. Simmons, N.L. 1990. A cultured human renal epithelioid cell line responsive to vasoactive intestinal peptide. Exp. Physiol. 75:309-319.
37. + T cell determinants to enable rational design and characterization of smallpox vaccines. J. Exp. Med. 201:95-104.
38. Yotnda, P., H. Onishi, H.E. Heslop, D. Shayakhmetov, A. Lieber, M. Brenner, and A. Davis. 2001. Efficient infection of primitive hematopoietic stem cells by modified adenovirus. Gene Ther. 8:930-937.
39. Khanna, R., S.R. Burrows, M.G. Kurilla, C.A. Jacob, I.S. Misko, T.B. Sculley, E. Kieff, and D.J. Moss. 1992. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J. Exp. Med. 176:169-176.